Beta Drugs Peer Comparison

NSE: BETA

₹2,201.00

₹6.80 (0.31%)

As on 28-Aug-2026IST

Market cap

₹2,448 Cr

Revenue (TTM)

₹362 Cr

P/E Ratio

59

P/B Ratio

9.3

Div. Yield

0 %

Edit

	Beta Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	2,448	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	362	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	42.42	414.00	288.22	-371.81	387.35
Net Margin (%)	11.50	11.23	14.79	-3.93	26.01
RoE (%)	23.95	8.38	29.77	-3.85	25.18
Price to Earnings	59.01	78.49	103.71	--	69.57
Price-To-Book	9.33	6.38	22.27	3.64	15.55

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Beta Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	362.36	3,012.00	1,284.27	9,151.18	1,006.88
Total Income	368.79	3,074.00	1,296.22	9,312.95	1,023.80
Total Expenditure	287.75	2,619.00	1,028.33	7,733.31	774.80
EBITDA	74.61	393.00	255.95	1,417.87	232.07
Depreciation	12.51	217.00	36.59	816.34	26.62
EBIT	62.09	176.00	219.36	601.53	205.45
Interest	6.99	254.00	36.78	421.59	6.22
Other Income	6.44	62.00	11.95	161.77	16.93
Exceptional Items	-4.57	--	--	--	--
Profit before Tax	56.97	-16.00	194.52	414.64	216.16
Provision for Tax	14.55	41.00	60.16	323.51	55.75
Profit after Tax	42.42	-57.00	134.36	91.13	160.42

Liabilities (₹ Cr)

	Beta Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	197.10	4,353.00	540.98	8,125.47	1,309.63
Minority Interest	--	304.00	0.00	--	10.45
Non-Current Liabilities	134.58	887.00	122.65	3,392.72	26.93
Current Liabilities	113.39	2,042.00	786.03	3,850.56	202.25
Total Liabilities	446.89	8,100.00	1,451.43	15,513.53	1,549.26

Assets (₹ Cr)

	Beta Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	103.33	5,017.00	386.29	9,487.47	757.63
Current Assets	341.73	2,465.00	1,063.37	5,881.28	791.64
Total Assets	446.89	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	138.06	1,859.00	393.17	4,720.27	8.18
Net Current Assets	228.35	423.00	277.34	2,030.72	589.39
Contingent Liabilities	1.73	770.26	12.25	99.76	15.38

Cashflow (₹ Cr)

	Beta Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	36.14	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	-35.72	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	117.97	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	118.39	-396.00	54.56	-25.99	155.52

Ratios

Profitability Ratios

	Beta Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	25.23	4.07	26.97	6.61	20.14
ROE (%)	23.95	-1.48	30.68	1.14	16.19
ROA (%)	11.99	-0.78	10.50	0.60	12.13
EBIT Margin (%)	22.37	15.11	20.86	17.26	24.73
Net Margin (%)	11.50	-1.85	10.37	0.98	15.67
Cash Profit Margin (%)	15.16	4.14	7.13	8.54	18.58

Growth Ratios

	Beta Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	22.54	7.65	50.40	11.99	40.34
EBIT Growth (%)	32.08	272.95	54.77	15.16	83.12
Net Profit Growth (%)	16.42	87.92	47.63	411.39	229.35
EPS Growth (%)	16.42	90.35	45.69	410.84	67.16
Book Value Growth (%)	25.45	29.77	42.49	2.28	94.96

Valuation Ratios

	Beta Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	45.35	0.00	0.00	326.26	62.97
Price / Book Value	9.76	5.31	0.00	3.69	15.26
Dividend Yield (%)	0.00	0.00	--	0.06	0.06
EV/EBITDA	23.62	54.36	1.09	21.49	79.31
Market Cap (₹ Cr)	1,923.53	23,064.69	0.00	29,731.27	19,988.69

Solvency Ratios

	Beta Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.70	0.43	0.76	0.59	0.01
Short term debt to equity ratio	0.03	0.11	0.54	0.12	0.01
Current Ratio	3.01	1.21	1.35	1.53	3.91
Quick Ratio	2.49	0.85	0.69	0.93	3.02
Interest Coverage	9.15	0.94	6.29	1.98	35.76

Operating Efficiency Ratios

	Beta Drugs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	28.31	21.95	25.21	25.67	28.85
Asset Turnover	1.02	0.53	1.87	0.70	0.76
Receivable days	91.57	60.36	47.59	77.05	90.06
Inventory Days	55.19	64.42	62.58	77.13	61.02
Payable days	139.01	218.94	228.78	173.49	96.06
Cash Conversion Cycle	7.75	-94.15	-118.62	-19.30	55.02